Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Lung Cancer

  Free Subscription


Articles published in J Thorac Cardiovasc Surg

Retrieve available abstracts of 111 articles:
HTML format



Single Articles


    December 2022
  1. DUAN X, Yang Z, Hao X, Zhou S, et al
    Early ligation of the pulmonary vein can reduce the dissemination of shed tumor cells during thoracoscopic lobectomy.
    J Thorac Cardiovasc Surg. 2022;164:1623-1635.
    PubMed     Abstract available


    November 2022
  2. LAPIDOT M, Mazzola E, Bueno R
    Outcomes of pleurectomy decortication in patients with biphasic mesothelioma.
    J Thorac Cardiovasc Surg. 2022;164:1340-1348.
    PubMed     Abstract available


  3. FRIEDBERG JS
    Commentary: "Can we" versus "should we": The defining dilemma of mesothelioma surgery.
    J Thorac Cardiovasc Surg. 2022;164:1349-1350.
    PubMed    


  4. TSUTANI Y, Ito M, Shimada Y, Ito H, et al
    The impact of epidermal growth factor receptor mutation status on adjuvant chemotherapy for patients with high-risk stage I lung adenocarcinoma.
    J Thorac Cardiovasc Surg. 2022;164:1306-1315.
    PubMed     Abstract available


    October 2022
  5. ALTORKI NK, Villena-Vargas J
    Commentary: Neoadjuvant immune checkpoint monotherapy for lung cancer: Has the train left the station?
    J Thorac Cardiovasc Surg. 2022 Oct 30:S0022-5223(22)01152.
    PubMed    


  6. RUSCH VW, Nicholas A, Patterson GA, Waqar SN, et al
    Surgical results of the Lung Cancer Mutation Consortium 3 trial: A phase II multicenter single-arm study to investigate the efficacy and safety of atezolizumab as neoadjuvant therapy in patients with stages IB-select IIIB resectable non-small cell lun
    J Thorac Cardiovasc Surg. 2022 Oct 8. pii: S0022-5223(22)01055.
    PubMed     Abstract available


    September 2022
  7. SAKOWITZ S, Verma A, Mabeza RM, Cho NY, et al
    Clinical and financial outcomes of pulmonary resection for lung cancer in safety-net hospitals.
    J Thorac Cardiovasc Surg. 2022 Sep 27. pii: S0022-5223(22)01026.
    PubMed     Abstract available


  8. QIU B, Ji Y, Zhang F, Bai G, et al
    Outcomes and experience of anatomical partial lobectomy.
    J Thorac Cardiovasc Surg. 2022;164:637-647.
    PubMed     Abstract available


  9. ZHANG Y, Chen H
    Commentary: Anatomical partial lobectomy: The indications should be better defined.
    J Thorac Cardiovasc Surg. 2022;164:648-649.
    PubMed    


    August 2022
  10. HASHIMOTO K, Ariyasu R, Ichinose J, Matsuura Y, et al
    Advances in the treatment of postoperative recurrence of non-small cell lung cancer and their impact on survival in Asian patients.
    J Thorac Cardiovasc Surg. 2022 Aug 25. pii: S0022-5223(22)00903.
    PubMed     Abstract available


  11. LEE B, Mynard N, Nasar A, Villena-Vargas J, et al
    Surgical resection after neoadjuvant durvalumab and radiation is feasible and safe in non-small cell lung cancer: Results from a randomized trial.
    J Thorac Cardiovasc Surg. 2022 Aug 6. pii: S0022-5223(22)00804.
    PubMed     Abstract available


  12. TILL BM, Mack S, Whitehorn G, Rahman U, et al
    Impact of stereotactic body radiation therapy volume on surgical patient selection, short-term survival, and long-term survival in early-stage non-small cell lung cancer.
    J Thorac Cardiovasc Surg. 2022 Aug 6. pii: S0022-5223(22)00816.
    PubMed     Abstract available


  13. LOGAN CD, Jacobs RC, Feinglass J, Lung K, et al
    National trends in the quality of segmentectomy for lung cancer.
    J Thorac Cardiovasc Surg. 2022 Aug 5. pii: S0022-5223(22)00821.
    PubMed     Abstract available


  14. LEE JM
    Commentary: The search for a chemotherapy-free immunotherapy regimen in resectable non-small cell lung cancer: The unmet need.
    J Thorac Cardiovasc Surg. 2022 Aug 3. pii: S0022-5223(22)00807.
    PubMed    


  15. DELMAN AM, Turner KM, Wima K, Simon VE, et al
    Offering lung resection to current smokers: An opportunity for more equitable care.
    J Thorac Cardiovasc Surg. 2022;164:400-408.
    PubMed     Abstract available


    July 2022
  16. KHO J, Mitchell J, Curry N, Di Chiara F, et al
    Should all patients receive extended thromboprophylaxis after resection of primary lung cancer?
    J Thorac Cardiovasc Surg. 2022 Jul 5. pii: S0022-5223(22)00712.
    PubMed     Abstract available


  17. LI D, Deng C, Wang S, Li Y, et al
    Ten-year follow-up of lung cancer patients with resected adenocarcinoma in situ or minimally invasive adenocarcinoma: Wedge resection is curative.
    J Thorac Cardiovasc Surg. 2022 Jul 5. pii: S0022-5223(22)00713.
    PubMed     Abstract available


  18. SULLIVAN KA, Farrokhyar F, Leontiadis GI, Patel YS, et al
    Routine systematic sampling versus targeted sampling during endobronchial ultrasound: A randomized feasibility trial.
    J Thorac Cardiovasc Surg. 2022;164:254-261.
    PubMed     Abstract available


  19. LIN J
    Commentary: Teach me to fish-spears, rods, and nets: Lymph node sampling during endobronchial ultrasound.
    J Thorac Cardiovasc Surg. 2022;164:263-264.
    PubMed    


  20. NA KJ, Kim YT
    Commentary: Targeted sampling during endobronchial ultrasound: Additional prerequisites for clinical implementation.
    J Thorac Cardiovasc Surg. 2022;164:262-263.
    PubMed    


  21. SATO M, Kobayashi M, Sakamoto J, Fukai R, et al
    The role of virtual-assisted lung mapping 2.0 combining microcoils and dye marks in deep lung resection.
    J Thorac Cardiovasc Surg. 2022;164:243-251.
    PubMed     Abstract available


    June 2022
  22. RUSCH VW
    Commentary: Surgical standardization in mesothelioma trials.
    J Thorac Cardiovasc Surg. 2022;163:1949-1950.
    PubMed    


  23. GIFFIN C, Kidane B
    Commentary: Less is maybe more: Sublobar resection in screen-detected lung cancers.
    J Thorac Cardiovasc Surg. 2022;163:1917-1918.
    PubMed    


  24. HASEGAWA S, Yokoi K, Okada M, Tanaka F, et al
    Neoadjuvant pemetrexed plus cisplatin followed by pleurectomy for malignant pleural mesothelioma.
    J Thorac Cardiovasc Surg. 2022;163:1940-1947.
    PubMed     Abstract available


  25. GRIFFIN CM, van Berkel VH
    Commentary: A return trip to MARS: Less may be more when treating mesothelioma.
    J Thorac Cardiovasc Surg. 2022;163:1948-1949.
    PubMed    


    May 2022
  26. LIN J
    Commentary: Maximum standardized uptake value is no crystal ball for candidate selection for sublobar resection: The future is cloudy (ground-glass).
    J Thorac Cardiovasc Surg. 2022;163:1667-1668.
    PubMed    


  27. GILES AE, Kidane B
    Commentary: Toward precision surgery: Advances in defining sublobar resection candidacy.
    J Thorac Cardiovasc Surg. 2022;163:1666-1667.
    PubMed    


  28. MURAOKA Y, Yoshida Y, Nakagawa K, Ito K, et al
    Maximum standardized uptake value of the primary tumor does not improve candidate selection for sublobar resection.
    J Thorac Cardiovasc Surg. 2022;163:1656-1665.
    PubMed     Abstract available


  29. ABDALLAH HM, Martinez-Meehan D, Lutfi W, Dhupar R, et al
    Adjuvant chemotherapy for pulmonary sarcomatoid carcinoma: A retrospective analysis of the National Cancer Database.
    J Thorac Cardiovasc Surg. 2022;163:1669-1681.
    PubMed     Abstract available


    April 2022
  30. FURRER K, Weder W, Eboulet EI, Betticher D, et al
    Extended resection for potentially operable patients with stage III non-small cell lung cancer after induction treatment.
    J Thorac Cardiovasc Surg. 2022 Apr 18. pii: S0022-5223(22)00403.
    PubMed     Abstract available


  31. STARNES SL
    Commentary: Artificial intelligence for pulmonary nodules: Machines to diagnosis cancer.
    J Thorac Cardiovasc Surg. 2022;163:1506-1507.
    PubMed    


  32. ASHRAF SF, Yin K, Meng CX, Wang Q, et al
    Predicting benign, preinvasive, and invasive lung nodules on computed tomography scans using machine learning.
    J Thorac Cardiovasc Surg. 2022;163:1496-1505.
    PubMed     Abstract available


  33. KNEUERTZ PJ, Yudovich MS, Amadi CC, Bashian E, et al
    Pulmonary artery size on computed tomography is associated with major morbidity after pulmonary lobectomy.
    J Thorac Cardiovasc Surg. 2022;163:1521-1529.
    PubMed     Abstract available


  34. EKEKE CN, Russell KL, Murthy P, Guo ZS, et al
    Intrapleural interleukin-2-expressing oncolytic virotherapy enhances acute antitumor effects and T-cell receptor diversity in malignant pleural disease.
    J Thorac Cardiovasc Surg. 2022;163:e313-e328.
    PubMed     Abstract available


    March 2022
  35. ISHIWATA T, Motooka Y, Ujiie H, Inage T, et al
    Endobronchial ultrasound-guided bipolar radiofrequency ablation for lung cancer: A first-in-human clinical trial.
    J Thorac Cardiovasc Surg. 2022 Mar 26. pii: S0022-5223(22)00344.
    PubMed     Abstract available


  36. CHIDI AP, Broderick SR
    Commentary: Perioperative systemic therapy in early-stage non-small cell lung cancer: The future is bright.
    J Thorac Cardiovasc Surg. 2022 Mar 24. pii: S0022-5223(22)00345.
    PubMed    


  37. HEIDEN BT, Subramanian MP, Liu J, Keith A, et al
    Long-term patient-reported outcomes after non-small cell lung cancer resection.
    J Thorac Cardiovasc Surg. 2022 Mar 12. pii: S0022-5223(22)00270.
    PubMed     Abstract available


  38. ELKIN PL, Mullin S, Tetewsky S, Resendez SD, et al
    Identification of patient characteristics associated with survival benefit from metformin treatment in patients with stage I non-small cell lung cancer.
    J Thorac Cardiovasc Surg. 2022 Mar 10. pii: S0022-5223(22)00241.
    PubMed     Abstract available


  39. LIN J
    Commentary: Reading the voxels: A fortune teller's nomogram to invasiveness in stage IA lung adenocarcinoma.
    J Thorac Cardiovasc Surg. 2022;163:816-817.
    PubMed    


  40. BRUNELLI A
    Commentary: Ground glass opacity: Is it the Holy Grail?
    J Thorac Cardiovasc Surg. 2022;163:802-803.
    PubMed    


  41. QIU ZB, Zhang C, Chu XP, Cai FY, et al
    Quantifying invasiveness of clinical stage IA lung adenocarcinoma with computed tomography texture features.
    J Thorac Cardiovasc Surg. 2022;163:805-815.
    PubMed     Abstract available


  42. VILLENA-VARGAS J, Lutton EM, Mynard N, Nasar A, et al
    Safety of lung cancer surgery during COVID-19 in a pandemic epicenter.
    J Thorac Cardiovasc Surg. 2022 Mar 1. pii: S0022-5223(22)00222.
    PubMed     Abstract available


    February 2022
  43. ALTORKI N, Villena-Vargas J, Wakelee H
    Adjuvant therapy for early-stage non-small cell lung cancer: The breaking of a new dawn.
    J Thorac Cardiovasc Surg. 2022 Feb 17. pii: S0022-5223(22)00202.
    PubMed    


  44. CASTRO PP, de Perrot M, Chua YC, Bezjak A, et al
    Importance of tumor size in resectable stage III-N2 non-small cell lung cancer.
    J Thorac Cardiovasc Surg. 2022 Feb 11. pii: S0022-5223(22)00195.
    PubMed     Abstract available


  45. STILES BM
    Commentary: Early stage epidermal growth factor receptor lung cancer: Skip to the good stuff?
    J Thorac Cardiovasc Surg. 2022 Feb 5. pii: S0022-5223(22)00125.
    PubMed    


  46. GRAY KD, Molena D
    Commentary: To cut is a chance to cure? Lessons to be learned from the PulMiCC trial.
    J Thorac Cardiovasc Surg. 2022;163:493-494.
    PubMed    


  47. VAN RAEMDONCK D, Van Cutsem E
    Commentary: A crusade against current pulmonary metastasectomy practice in colorectal cancer patients: Do the con arguments remain after the PulMiCC trial?
    J Thorac Cardiovasc Surg. 2022;163:491-492.
    PubMed    


  48. ALTORKI N, Vimolratana M
    Commentary: Surgery for ground-glass nodules: Free lunch or slippery slope?
    J Thorac Cardiovasc Surg. 2022;163:465-466.
    PubMed    


  49. PASS HI
    Commentary: Pulmonary metastasectomy efficacy: A game of clones?
    J Thorac Cardiovasc Surg. 2022;163:503-510.
    PubMed    


  50. BLUMENTHALER AN, Antonoff MB
    Commentary: The best outcomes for pulmonary metastasectomy come from picking the right patients.
    J Thorac Cardiovasc Surg. 2022;163:483-484.
    PubMed    


  51. TREASURE T, Dunning J, Williams NR, Macbeth F, et al
    Lung metastasectomy for colorectal cancer: The impression of benefit from uncontrolled studies was not supported in a randomized controlled trial.
    J Thorac Cardiovasc Surg. 2022;163:486-490.
    PubMed    


  52. ZHANG Y, Ma X, Shen X, Wang S, et al
    Surgery for pre- and minimally invasive lung adenocarcinoma.
    J Thorac Cardiovasc Surg. 2022;163:456-464.
    PubMed     Abstract available


  53. LIU Z, Yin J, Zhou Q, Yang J, et al
    Survival after pulmonary metastasectomy for relapsed osteosarcoma.
    J Thorac Cardiovasc Surg. 2022;163:469-479.
    PubMed     Abstract available


  54. MATSUURA Y, Ninomiya H, Ichinose J, Nakao M, et al
    Prognostic impact and distinctive characteristics of surgically resected anaplastic lymphoma kinase-rearranged lung adenocarcinoma.
    J Thorac Cardiovasc Surg. 2022;163:441-451.
    PubMed     Abstract available


    January 2022
  55. SEPESI B, Zhou N, William WN Jr, Lin HY, et al
    Surgical outcomes after nivolumab or nivolumab with ipilimumab treatment in patients with non-small cell lung cancer.
    J Thorac Cardiovasc Surg. 2022 Jan 23. pii: S0022-5223(22)00089.
    PubMed     Abstract available


  56. WATANABE I, Hattori A, Fukui M, Matsunaga T, et al
    Pulmonary artery reconstruction for non-small cell lung cancer: Surgical management and long-term outcomes.
    J Thorac Cardiovasc Surg. 2022 Jan 22. pii: S0022-5223(22)00087.
    PubMed     Abstract available


  57. LANUTI M
    Commentary: Induction antiangiogenesis for stage IIIA-N2 non-small cell lung cancer is not the answer yet: Optimal induction for operable disease is a clear work in progress.
    J Thorac Cardiovasc Surg. 2022 Jan 8. pii: S0022-5223(22)00007.
    PubMed    


  58. LAZAR JF, Herrera LJ
    Commentary: Ablation and endobronchial ultrasound for treating early lung cancer: Two great technologies that may work great together!
    J Thorac Cardiovasc Surg. 2022 Jan 8. pii: S0022-5223(22)00009.
    PubMed    


  59. LINDEN PA
    Commentary: Spread the news: Spread through air spaces matters.
    J Thorac Cardiovasc Surg. 2022;163:285.
    PubMed    


  60. LIN J
    Commentary: Should we start spreading the news? Prognostic influence of spread through air spaces in early-stage lung adenocarcinoma.
    J Thorac Cardiovasc Surg. 2022;163:286-287.
    PubMed    


  61. DAVID EA
    Commentary: STAS is here to STAY.
    J Thorac Cardiovasc Surg. 2022;163:287-288.
    PubMed    


  62. ZHANG Y, Chen H
    Commentary: Is sublobar resection enough for ground-glass opacity-dominant lung adenocarcinoma?
    J Thorac Cardiovasc Surg. 2022;163:303-304.
    PubMed    


  63. ZHANG Y, Cao Y, Li H
    REPLY: THE CONTINUED DEBATE ON ROBOTIC SEGMENTECTOMY-AGREE TO DISAGREE.
    J Thorac Cardiovasc Surg. 2022;163:e99-e100.
    PubMed    


  64. JUNG W, Chung JH, Yum S, Kim K, et al
    The differential prognostic impact of spread through air spaces in early-stage lung adenocarcinoma after lobectomy according to the pT descriptor.
    J Thorac Cardiovasc Surg. 2022;163:277-284.
    PubMed     Abstract available


  65. CORSINI EM, Ripley RT
    Commentary: KRAS-mutant lung adenocarcinomas-a work in progress.
    J Thorac Cardiovasc Surg. 2022;163:e87-e88.
    PubMed    


  66. MA Z, Zhang Y, Deng C, Fu F, et al
    The prognostic value of Kirsten rat sarcoma viral oncogene homolog mutations in resected lung adenocarcinoma differs according to clinical features.
    J Thorac Cardiovasc Surg. 2022;163:e73-e85.
    PubMed     Abstract available


    December 2021
  67. CONNOLLY JG, Fiasconaro M, Tan KS, Cirelli MA Jr, et al
    Postinduction therapy pulmonary function retesting is necessary before surgical resection for non-small cell lung cancer.
    J Thorac Cardiovasc Surg. 2021 Dec 23. pii: S0022-5223(21)01818.
    PubMed     Abstract available


  68. TAKAMOCHI K, Suzuki K, Tsuboi M, Niho S, et al
    Randomized phase II trial of pemetrexed-cisplatin plus bevacizumab or thoracic radiotherapy followed by surgery for stage IIIA (N2) nonsquamous non-small cell lung cancer.
    J Thorac Cardiovasc Surg. 2021 Dec 9. pii: S0022-5223(21)01714.
    PubMed     Abstract available


  69. SAVITCH SL, Grenda TR, Yi M, Till B, et al
    Facility-level national trends in racial disparities of surgical therapy for early-stage lung cancer.
    J Thorac Cardiovasc Surg. 2021 Dec 9. pii: S0022-5223(21)01716.
    PubMed     Abstract available


  70. ARNOLD BN, Antonoff MB
    Commentary: Optimizing resources in lung cancer survivorship.
    J Thorac Cardiovasc Surg. 2021 Dec 4. pii: S0022-5223(21)01691.
    PubMed    


  71. CHEN J, Soultanis KM, Sun F, Gonzalez-Rivas D, et al
    Outcomes of sleeve lobectomy versus pneumonectomy: A propensity score-matched study.
    J Thorac Cardiovasc Surg. 2021;162:1619-1628.
    PubMed     Abstract available


    November 2021
  72. SHENOY R, Okereke I
    Commentary: Lung cancer resections during the pandemic.
    J Thorac Cardiovasc Surg. 2021 Nov 20. pii: S0022-5223(21)01651.
    PubMed    


  73. CHANG SH
    Commentary: Surgery versus stereotactic body radiation therapy for patients with renal dysfunction and non-small cell lung cancer: The answer is still not clear.
    J Thorac Cardiovasc Surg. 2021 Nov 20. pii: S0022-5223(21)01647.
    PubMed    


  74. KESHAVA HB, Tan KS, Dycoco J, Huang J, et al
    Long-term assessment of efficacy with a novel thoracic survivorship program for patients with lung cancer.
    J Thorac Cardiovasc Surg. 2021 Nov 20. pii: S0022-5223(21)01635.
    PubMed     Abstract available


    October 2021
  75. POULSON MR, Kenzik KM, Singh S, Pavesi F, et al
    Redlining, structural racism, and lung cancer screening disparities.
    J Thorac Cardiovasc Surg. 2021 Oct 14. pii: S0022-5223(21)01421.
    PubMed     Abstract available


  76. HANNA WC
    Commentary: Wedge versus segmentectomy-It is best to err on the side of caution.
    J Thorac Cardiovasc Surg. 2021;162:1254.
    PubMed    


    September 2021
  77. DELMAN AM, Van Haren RM
    Commentary: Mitigating lung cancer mortality in patients with end-stage renal disease.
    J Thorac Cardiovasc Surg. 2021 Sep 27. pii: S0022-5223(21)01389.
    PubMed    


  78. SAITO T, Murakawa T, Shintani Y, Okami J, et al
    Preoperative renal dysfunction and long-term survival after surgery for non-small cell lung cancer.
    J Thorac Cardiovasc Surg. 2021 Sep 10. pii: S0022-5223(21)01311.
    PubMed     Abstract available


  79. FARMER DM, Ripley RT
    Commentary: EGFR mutations lung adenocarcinoma-Is the driver removed with the lobe?
    J Thorac Cardiovasc Surg. 2021;162:675-676.
    PubMed    


  80. KHORFAN R, Cooke DT, Meguid RA, Backhus L, et al
    Institutional factors associated with adherence to quality measures for stage I and II non-small cell lung cancer.
    J Thorac Cardiovasc Surg. 2021;162:649-660.
    PubMed     Abstract available


  81. DENG C, Zhang Y, Ma Z, Fu F, et al
    Prognostic value of epidermal growth factor receptor gene mutation in resected lung adenocarcinoma.
    J Thorac Cardiovasc Surg. 2021;162:664-674.
    PubMed     Abstract available


    August 2021
  82. BRUNELLI A
    Commentary: Lobectomy should be the exception rather than the rule to resect screen-detected stage I non-small cell lung cancer.
    J Thorac Cardiovasc Surg. 2021 Aug 27. pii: S0022-5223(21)01253.
    PubMed    


  83. EGYUD M, Burt BM
    Commentary: The structure of structural racism revealed by lung cancer screening.
    J Thorac Cardiovasc Surg. 2021 Aug 24. pii: S0022-5223(21)01248.
    PubMed    


  84. SIENICKI E, Onaitis M
    Commentary: New players in epidermal growth factor receptor tyrosine kinase inhibitor resistance.
    J Thorac Cardiovasc Surg. 2021;162:474-475.
    PubMed    


  85. FU F, Zhang Y, Wang S, Li Y, et al
    Computed tomography density is not associated with pathological tumor invasion for pure ground-glass nodules.
    J Thorac Cardiovasc Surg. 2021;162:451-459.
    PubMed     Abstract available


  86. YOSHIYASU N, Kojima F, Hayashi K, Bando T, et al
    Radiomics technology for identifying early-stage lung adenocarcinomas suitable for sublobar resection.
    J Thorac Cardiovasc Surg. 2021;162:477-485.
    PubMed     Abstract available


    July 2021
  87. PENNATHUR A, Brunelli A, Criner G, Keshavarz H, et al
    Definition and assessment of high risk in patients considered for lobectomy for stage I non-small cell lung cancer: The American Association for Thoracic Surgery expert panel consensus document.
    J Thorac Cardiovasc Surg. 2021 Jul 29. pii: S0022-5223(21)01129.
    PubMed     Abstract available


  88. CHUDGAR NP, Stiles BM
    Commentary: Adjuvant therapy in resected T1 2N0 non-small cell lung cancer: Surgeons should lead.
    J Thorac Cardiovasc Surg. 2021 Jul 14. pii: S0022-5223(21)01036.
    PubMed    


  89. WOODARD GA, Li A, Boffa DJ
    Role of adjuvant therapy in T1-2N0 resected non-small cell lung cancer.
    J Thorac Cardiovasc Surg. 2021 Jul 10. pii: S0022-5223(21)01032.
    PubMed    


  90. WANG SX, Marshall MB
    Commentary: A new hope: Do ADAURA trial results change the paradigm for treatment of resectable lung adenocarcinoma?
    J Thorac Cardiovasc Surg. 2021;162:293-294.
    PubMed    


  91. ANTONOFF MB, Morris VK
    Reply from author: Biology is king, but metastasectomy still has a role for properly selected patients.
    J Thorac Cardiovasc Surg. 2021;162:e136-e138.
    PubMed    


  92. CAMERON RB
    Reply: Discussions regarding pulmonary metastasectomy are similar to American politics: Both are extremely polarizing, unsatisfying, inconclusive, and undertaken at your own peril.
    J Thorac Cardiovasc Surg. 2021;162:e135-e136.
    PubMed    


  93. HIRPARA DH, Kidane B
    Commentary: VATS, RATS, stats, and some caveats.
    J Thorac Cardiovasc Surg. 2021;162:269-270.
    PubMed    


  94. SIHAG S
    Commentary: Sarcomas and sarcomatoid tumors of the lung...not your average lung cancers.
    J Thorac Cardiovasc Surg. 2021;162:285-286.
    PubMed    


  95. JONES DR, Wu YL, Tsuboi M, Herbst RS, et al
    Targeted therapies for resectable lung adenocarcinoma: ADAURA opens for thoracic oncologic surgeons.
    J Thorac Cardiovasc Surg. 2021;162:288-292.
    PubMed    


  96. CORSINI EM, Mitchell KG, Correa A, Morris VK, et al
    Effect of primary colorectal cancer tumor location on survival after pulmonary metastasectomy.
    J Thorac Cardiovasc Surg. 2021;162:296-305.
    PubMed     Abstract available


  97. ROBINSON LA, Babacan NA, Tanvetyanon T, Henderson-Jackson E, et al
    Results of treating primary pulmonary sarcomas and pulmonary carcinosarcomas.
    J Thorac Cardiovasc Surg. 2021;162:274-284.
    PubMed     Abstract available


  98. KAMEL MK, Lee B, Harrison SW, Port JL, et al
    Sublobar resection is comparable to lobectomy for screen-detected lung cancer.
    J Thorac Cardiovasc Surg. 2021 Jul 1. pii: S0022-5223(21)01011.
    PubMed     Abstract available


    May 2021
  99. ISBELL JM, Li BT, Gomez DR
    The emerging role of local therapy in oligometastatic non-small cell lung cancer.
    J Thorac Cardiovasc Surg. 2021 May 29. pii: S0022-5223(21)00875.
    PubMed    


  100. DONINGTON JS
    Commentary: Why do we operate in metastatic lung cancer?
    J Thorac Cardiovasc Surg. 2021 May 8. pii: S0022-5223(21)00771.
    PubMed    


  101. WIGHTMAN SC, Kim AW
    Commentary: When less is more for lung cancers.
    J Thorac Cardiovasc Surg. 2021;161:1650-1651.
    PubMed    


  102. CERFOLIO RJ
    Commentary: Let us raise the bar higher for better patient outcomes.
    J Thorac Cardiovasc Surg. 2021;161:1649-1650.
    PubMed    


  103. WEKSLER B, Sullivan JL, Schumacher LY
    Randomized trial of bupivacaine with epinephrine versus bupivacaine liposome suspension in patients undergoing minimally invasive lung resection.
    J Thorac Cardiovasc Surg. 2021;161:1652-1661.
    PubMed     Abstract available


    April 2021
  104. FERNANDEZ R, Ahmad U
    Commentary: A new hope-neoadjuvant immunotherapy for resectable non-small cell lung cancer.
    J Thorac Cardiovasc Surg. 2021 Apr 27. pii: S0022-5223(21)00740.
    PubMed    


  105. BONNER SN, Wakeam E
    The volume-outcome relationship in lung cancer surgery: The impact of the social determinants of health care delivery.
    J Thorac Cardiovasc Surg. 2021 Apr 20. pii: S0022-5223(21)00593.
    PubMed    


  106. TONG BC, Gu L, Wang X, Wigle DA, et al
    Perioperative outcomes of pulmonary resection after neoadjuvant pembrolizumab in patients with non-small cell lung cancer.
    J Thorac Cardiovasc Surg. 2021 Apr 9. pii: S0022-5223(21)00583.
    PubMed     Abstract available


  107. HOD T, Freedberg KJ, Motwani SS, Chen M, et al
    Acute kidney injury after cytoreductive surgery and hyperthermic intraoperative cisplatin chemotherapy for malignant pleural mesothelioma.
    J Thorac Cardiovasc Surg. 2021;161:1510-1518.
    PubMed     Abstract available


    March 2021
  108. ELY S, Jiang SF, Dominguez DA, Patel AR, et al
    Effect of thoracic surgery regionalization on long-term survival after lung cancer resection.
    J Thorac Cardiovasc Surg. 2021 Mar 20. pii: S0022-5223(21)00530.
    PubMed     Abstract available


  109. ANTONOFF MB, Sofocleous CT, Callstrom MR, Nguyen QN, et al
    The roles of surgery, stereotactic radiation, and ablation for treatment of pulmonary metastases.
    J Thorac Cardiovasc Surg. 2021 Mar 6. pii: S0022-5223(21)00423.
    PubMed    


  110. DONAHOE LL, Nason GJ, Bedard PL, Hansen AR, et al
    Pathologic concordance of resected metastatic nonseminomatous germ cell tumors in the chest.
    J Thorac Cardiovasc Surg. 2021;161:856-868.
    PubMed     Abstract available


  111. SHEMANSKI KA, Farias A, Lieu D, Kim AW, et al
    Understanding thoracic surgeons' perceptions of administrative database analyses and guidelines in clinical decision-making.
    J Thorac Cardiovasc Surg. 2021;161:807-816.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: